Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States.
+ 2 more risks
Excellent balance sheet with limited growth.
Share Price & News
How has Idera Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: HXXB's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: HXXB underperformed the German Biotechs industry which returned 3.7% over the past year.
Return vs Market: HXXB underperformed the German Market which returned 6.1% over the past year.
Price Volatility Vs. Market
How volatile is Idera Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Idera Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate HXXB's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate HXXB's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: HXXB is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: HXXB is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate HXXB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: HXXB is good value based on its PB Ratio (1.2x) compared to the DE Biotechs industry average (3.2x).
How is Idera Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HXXB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: HXXB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: HXXB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: HXXB's revenue (66.1% per year) is forecast to grow faster than the German market (5.1% per year).
High Growth Revenue: HXXB's revenue (66.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HXXB is forecast to be unprofitable in 3 years.
How has Idera Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HXXB is currently unprofitable.
Growing Profit Margin: HXXB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: HXXB is unprofitable, and losses have increased over the past 5 years at a rate of -6.8% per year.
Accelerating Growth: Unable to compare HXXB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HXXB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: HXXB has a negative Return on Equity (-120.75%), as it is currently unprofitable.
How is Idera Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: HXXB's short term assets ($45.1M) exceed its short term liabilities ($7.8M).
Long Term Liabilities: HXXB has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: HXXB is debt free.
Reducing Debt: HXXB has no debt compared to 5 years ago when its debt to equity ratio was 1.6%.
Inventory Level: HXXB has a low level of unsold assets or inventory.
Debt Coverage by Assets: HXXB's debt is not covered by short term assets (assets are -1287.8x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HXXB has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: HXXB has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of -12.9% each year.
What is Idera Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HXXB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate HXXB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HXXB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HXXB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HXXB's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Vinnie, Vin Milano (55yo)
Mr. Vincent J. Milano, also known as Vinnie and Vin, serves as Director at Aclaris Therapeutics, Inc. since January 7, 2020. He has been the Chief Executive Officer and President at Idera Pharmaceuticals, ...
CEO Compensation Analysis
Compensation vs Market: Vinnie, Vin's total compensation ($USD1.78M) is above average for companies of similar size in the German market ($USD415.76K).
Compensation vs Earnings: Vinnie, Vin's compensation has increased whilst the company is unprofitable.
|Senior VP & CFO||1.3yrs||US$553.87k||0.030% $13.0k|
|Senior Vice President of Business Development & Strategic Planning||5.1yrs||US$977.45k||0.010% $4.3k|
|Senior Vice President of IR & Corporate Communications||5.2yrs||no data||no data|
|Senior VP||1.4yrs||no data||0.027% $11.4k|
|Senior Vice President of Human Resources||5yrs||no data||no data|
|Senior VP & Chief Medical Officer||0.6yrs||no data||no data|
|Medical Director & Global Clinical Lead for Oncology||0yrs||no data||no data|
Experienced Management: HXXB's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
|Director||0.8yrs||no data||0.039% $16.6k|
|Independent Director||1.4yrs||US$142.14k||0.080% $34.5k|
|Independent Director||4.1yrs||US$100.99k||0.0030% $1.3k|
|Director||0.8yrs||no data||no data|
|Independent Director||6.1yrs||US$100.46k||0.035% $14.9k|
|Independent Director||1.2yrs||US$51.86k||0.071% $30.4k|
Experienced Board: HXXB's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: HXXB insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.1%.
Idera Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Idera Pharmaceuticals, Inc.
- Ticker: HXXB
- Exchange: DB
- Founded: 1989
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$46.773m
- Listing Market Cap: US$42.993m
- Shares outstanding: 28.87m
- Website: https://www.iderapharma.com
Number of Employees
- Idera Pharmaceuticals, Inc.
- 505 Eagleview Boulevard
- Suite 212
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IDRA||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Jan 1996|
|HXXB||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jan 1996|
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. It offers Tilsotolimod, a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma, and colorectal cancer. The company was founded in 1989 and is based in Exton, Pennsylvania.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/25 21:35|
|End of Day Share Price||2020/02/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.